Abstract
HER3-DXd, a first-in-class HER3 directed antibody drug conjugate, has demonstrated clinically meaningful antitumor activity in heavily pre-treated HER2-negative (HER2-) metastatic breast cancer (BC) across a broad range of HER3 expression levels. TOT-HER3 aims to generate translational data and to explore potential predictive biomarkers of HER3-DXd activity. Recently, the results from Part A of the trial showed that one dose of HER3-DXd is associated with clinical response, increased immune infiltration and proliferation suppression in hormone receptor positive (HR+)/HER2- early BC (EBC) (Prat et al.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
